Patent · US Active

Antibody frameworks

US11427628B2 · kind B2 · utility

0Cited by

2References

4Claims

0Family size

Assignee

Numab Therapeutics AG · CH

Inventors

Sebastian Meyer · Bielefeld, DE
David Urech · Jona, CH

Key dates

Filing date	Oct 10, 2018
Grant date	Aug 30, 2022
Priority date	—
Expiry date	Mar 25, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to antibody light chain framework regions I to III from Vκ and framework region IV from Vλ, with high stability and reduced aggregation propensity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.